Drug maker Lupin on Monday said it has received approval from the US health regulator to market a generic medication for Human Immunodeficiency Virus. The company has received tentative approval from the US Food and Drug Administration for Darunavir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide tablets, the company said in a statement.
The company's product has been found to be therapeutically equivalent to the reference listed drug Symtuza tablets, 800 mg/150 mg/200 mg/10 mg of Janssen Products, LP, it added.
Lupin is the exclusive first-to-file for this product, it stated.
As per the IQVIA MAT December 2024 data, Darunavir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide tablets had estimated annual sales of $1,374 million in the US.
Shares of Lupin were trading 1.29% down at Rs 2,028.70 apiece on BSE.
RECOMMENDED FOR YOU
Stocks To Buy, Sell, Or Hold: Shrikant Chouhan's Insights On SBI, Lupin And Gujarat Narmada
Jul 02, 2025
Lupin To Spin Off Healthcare Division
Jul 01, 2025
AI’s Dark Side: OpenAI’s o3 Model Defies Human Commands To Shut Down; Elon Musk Calls It ‘Concerning’
May 26, 2025
Lupin Q4 Results Review: Systematix Recommends 'Hold' Post Inline Earnings, Revises Target Price
May 16, 2025
POPULAR